Aromatase inhibitors as upfront therapy for early-stage breast cancer
In upfront therapy after breast surgery, aromatase inhibitors are taken for five years. The aromatase inhibitors anastrozole and letrozole have been approved for use in upfront therapy in Germany.
In 2016, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of aromatase inhibitors used as upfront therapy for women with early-stage breast cancer.
The Institute analyzed how aromatase inhibitors as upfront therapy compared to standard treatments such as tamoxifen. The Institute found two relevant studies in this area. One study involving 6,241 women compared anastrozole with tamoxifen. The other study compared letrozole with tamoxifen and analyzed the data from 4,922 women. The main results are described below.